Pyrrolo(3,4-c)pyrazole derivatives active as kinase inhibitors

Details for Australian Patent Application No. 2004255347 (hide)

Owner Pfizer Italia S.r.l.

Inventors Moll, Jurgen; Varasi, Mario; Vianello, Paola; Forte, Barbara; Fancelli, Daniele

Agent Davies Collison Cave

Pub. Number AU-B-2004255347

PCT Pub. Number WO2005/005427

Priority 60/485,814 09.07.03 US

Filing date 8 July 2004

Wipo publication date 20 January 2005

Acceptance publication date 8 April 2010

International Classifications

A61K 31/4162 (2006.01) - condensed with heterocyclic ring systems

A61P 35/00 (2006.01) Antineoplastic agents

C07D 487/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

Event Publications

19 January 2006 PCT application entered the National Phase

  PCT publication WO2005/005427 Priority application(s): WO2005/005427

5 June 2008 Assignment before Grant

  Pharmacia Italia S.p.A. The application has been assigned to Pfizer Italia S.r.l.

8 April 2010 Application Accepted

  Published as AU-B-2004255347

5 August 2010 Standard Patent Sealed

24 February 2011 Assignment Registered

  Pfizer Italia S.r.l. The patent has been assigned to Nerviano Medical Sciences S.r.l.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004255351-Steroid modified chacotrioses and solatrioses

2004255344-Benzofuran derivatives and their use in the treatment of microbial infections